LENZ — LENZ Therapeutics
Median target
$7
calls from the last 12 months
Implied return
+100.0%
median target vs. price
Coverage
4 analysts · 4 calls
updated in the last 12 months
Consensus
2/2/0+2 net
Buy / Hold / Sell
Which analysts are behind LENZ's consensus?
See every current rating, price target and the analysts' track records for LENZ Therapeutics — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 4 analysts with calls on LENZ updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
LENZ elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-11-04 | Insiders | Bml Investment Partners, L.P. | 13G stake | 6.7% of class · new position | 2.1M sh |
| 2026-10-29 | Insiders | Ra Capital Management, L.P. +310% owner | Insider sale | 2.2M sh @ $3.36 | $7.3M |
| 2026-10-29 | Insiders | Ra Capital Management, L.P. +310% owner | Insider sale | 452.0K sh @ $3.36 | $1.5M |
| 2026-10-29 | Insiders | Ra Capital Management, L.P. +310% owner | Insider sale | 107.2K sh @ $3.36 | $360K |
More: insider activity · executive branch · trending